Ahmed O Kaseb, MD

Peer-Reviewed Articles

1. Han, Y, Shaw, VR, Byun, J, Thrift, AP, Zhu, C, Li, D, Hatia, RI, Kelley, RK, Cleary, S, Lok, AS, Bracci, PM, Permuth, JB, Bucur, R, Knox, J, Yuan, JM, Singal, AG, Jalal, P, Ghobrial, RM, Kono, Y, Shah, DJ, Nguyen, MH, Parikh, ND, Kim, RD, Wu, HC, El-Serag, H, Chang, P, Chun, YS, Gu, J, Huff, C, Rashid, A, Hwang, LY, Klein, AP, Khaderi, SA, Kaseb, A, McGlynn, KA, Roberts, LR, Hassan, MM, Amos, CI. Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits. International journal of cancer 158(5):1193-1203, 2026. e-Pub 2026. PMID: 41013983.
2. Kodali, S, Connor, AA, Victor, DW, Abdelrahim, M, Elaileh, A, Patel, K, Brombosz, EW, Graviss, EA, Nguyen, DT, Xu, S, Moore, LW, Schwartz, MR, Dhingra, S, Basra, T, Jones-Pauley, MR, Noureddin, M, Mobley, CM, Hobeika, MJ, Simon, CJ, Lee Cheah, Y, Heyne, K, Kaseb, A, Saharia, A, Gaber, AO, Ghobrial, RM. Incidental Combined Hepatocellular-Cholangiocarcinoma in Liver Transplant Recipients. Transplant International 38, 2026. e-Pub 2026. PMID: 41685088.
3. Meyer, T, Finn, RS, Borad, MJ, Mahipal, A, Edeline, J, Houot, R, Hausner, PF, Hollebecque, A, Goyal, L, Frigault, M, Evans, TR, Wong, KM, Tan, BR, Mitry, E, Sarker, D, Feun, L, El-Rayes, BF, Thistlethwaite, FC, Kaseb, A, Alese, OB, Jin, Z, Cirillo, C, Bruix, J, Roddie, C, Noto, P, Fayngerts, S, Cristiani, S, Sampson, J, Bai, J, Isabelle, M, Broad, R, Sun, A, Norry, E, Sangro, B. Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. Journal of Hepatology 84(1):113-121, 2026. e-Pub 2026. PMID: 40812667.
4. Eid, JR, Haddad, A, Hassan, MM, Amin, H, Newhook, TE, Chun, YS, Tzeng, CD, Vauthey, JN, Tran Cao, HS, Kaseb, A. Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma. Journal of Gastrointestinal Surgery 30(1), 2026. e-Pub 2026. PMID: 41197829.
5. Qin, SK, Gu, S, Chan, SL, Bai, YX, Ren, ZG, Lin, X, Chen, Z, Jia, W, Jin, Yd, Guo, Y, Hu, XH, Meng, Z, Liang, J, Xiong, J, Ren, H, Yang, F, Li, W, Chen, Y, Zeng, Y, Xu, L, Yuan, X, Li, D, Sultanbaev, A, Pazgan-Simon, M, Pisetska, M, Melisi, D, Ponomarenko, D, Du, J, Shi, W, Cheng, AL, Kaseb, A, Vogel, A. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310). The lancet oncology 26(12):1598-1611, 2025. e-Pub 2025. PMID: 41308676.
6. De, BS, Dogra, P, Zaid, M, Elganainy, D, Sun, K, Amer, A, Wang, CX, Rooney, M, Chang, E, Kang, H, Wang, Z, Bhosale, PR, Odisio, BC, Newhook, TE, Tzeng, CD, Tran Cao, HS, Chun, YS, Vauthey, JN, Lee, SS, Kaseb, A, Raghav, KS, Javle, M, Minsky, B, Noticewala, SS, Holliday, EB, Smith, GL, Koong, AC, Das, P, Cristini, V, Ludmir, EB, Koay, EJ. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. npj Systems Biology and Applications 11(1), 2025. e-Pub 2025. PMID: 41387975.
7. Hernandez Vargas, S, Aghaamiri, S, Adams, JT, Bateman, TM, Acidi, B, Ghosh, SC, Khalaj, V, Kaseb, A, Tran Cao, HS, Momeny, M, Azhdarinia, A. Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma. Current Oncology 32(9), 2025. e-Pub 2025. PMID: 41002582.
8. Odisio, BC, Albuquerque, J, Lin, YM, Anderson, BM, OConnor, C, Rigaud, B, Briones-Dimayuga, M, Jones, AK, Fellman, B, Huang, SY, Kuban, JD, Metwalli, ZA, Sheth, RA, Habibollahi, P, Patel, MN, Shah, KY, Cox, V, Kang, HC, Morris, VK, Kopetz, S, Javle, M, Kaseb, A, Tzeng, CW, Cao, HT, Newhook, TE, Chun, YS, Vauthey, JN, Gupta, S, Paolucci, I, Brock, K. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL). The Lancet Gastroenterology and Hepatology 10(5):442-451, 2025. e-Pub 2025. PMID: 40090348.
9. Tsimberidou, AM, Vining, D, Arora, SP, De Achaval, S, Larson, J, Kauh, J, Cartwright, CA, Avritscher, R, Alibhai, I, Tweardy, D, Kaseb, A. Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clinical Cancer Research 31(6):965-974, 2025. e-Pub 2025. PMID: 39792482.
10. Wu, M, Fulgenzi, CM, D’Alessio, A, Cortellini, A, Celsa, C, Manfredi, GF, Stefanini, B, Wu, YL, Huang, YH, Saeed, A, Pirozzi, A, Pressiani, T, Rimassa, L, Schoenlein, M, Schulze, K, von Felden, J, Mohamed, Y, Kaseb, A, Vogel, A, Roehlen, N, Silletta, M, Nishida, N, Kudo, M, Vivaldi, C, Balcar, L, Scheiner, B, Pinter, M, Singal, AG, Glover, J, Ulahannan, SV, Foerster, F, Weinmann, A, Galle, PR, Parikh, ND, Hsu, WF, Parisi, A, Chon, HJ, Pinato, DJ, Ang, CS. Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab. JHEP Reports 7(2), 2025. e-Pub 2025. PMID: 39877031.
11. Hassanain, H, Connor, AA, Brombosz, EW, Patel, K, Elaileh, A, Basra, T, Kodali, S, Victor, DW, Simon, CJ, Cheah, YL, Hobeika, MJ, Mobley, CM, Saharia, A, Dhingra, S, Schwartz, MR, Maqsood, A, Heyne, K, Kaseb, A, Vauthey, JN, Gaber, AO, Abdelrahim, M, Ghobrial, RM. Sorafenib as Adjuvant Therapy Post-Liver Transplant. Transplantation Direct 11(2):e1746, 2025. e-Pub 2025. PMID: 39866680.
12. Hatia, RI, Hwang, LY, Li, R, Troisi, CL, Jalal, P, Amos, CI, Gomez, HF, Chun, YS, Rashid, A, Kaseb, A, Scheet, PA, Hassan, MM. Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus. Journal of Hepatocellular Carcinoma 12:93-106, 2025. e-Pub 2025. PMID: 39867264.
13. Momeny, M, Aghaamiri, S, Hernandez Vargas, S, Acidi, B, Ghosh, SC, Bateman, TM, Adams, JT, Khalaj, V, Kaseb, A, Tran Cao, HS, Azhdarinia, A. SSTR2-Targeted Theranostics in Hepatocellular Carcinoma. Cancers 17(2), 2025. e-Pub 2025. PMID: 39857944.
14. Finn, RS, Iyer, R, Kalman, RS, Parikh, ND, Cabrera, R, Babajanyan, S, Kaseb, A. Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 12:231-246, 2025. e-Pub 2025. PMID: 39935697.
15. Eid, JR, Yalciner, M, Xiao, L, Sun, R, Kannan, MK, Hassan, MM, Rashid, A, Chamseddine, SM, Tran Cao, HS, Amin, H, Kaseb, A. Circulating Fibroblast Growth Factor 21 (FGF21) as a Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 12:2709-2722, 2025. e-Pub 2025. PMID: 41399394.
16. Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO. Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma. J Immunother Precis Oncol 7(4):255-262, 2024. e-Pub 2024. PMID: 39524465.
17. DeAzevedo R, Steiner M, Turner BX, Liu A, Newton S, Schmidt J, Fleming R, Tolentino A, Kaseb AO, Curran MA. Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39477243.
18. LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO. Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma. Oncology 103(6):1-20, 2024. e-Pub 2024. PMID: 39427654.
19. Lee SH, Yim SY, Kim JH, Lee SS, Kaseb AO, Lee JS. Correspondence on Letter regarding "Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response.". Clin Mol Hepatol, 2024. e-Pub 2024. PMID: 39370716.
20. Yim SY, Lee SH, Kim JH, Lee SS, Kaseb AO, Lee JS. Correspondence on Letter regarding "Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors". Clin Mol Hepatol 31(1):e84-e86, 2024. e-Pub 2024. PMID: 39370715.
21. Lee SH, Yim SY, Kim JH, Lee SS, Kaseb AO, Wei P, Lee JS. Correspondence on Letter regarding "Comprehensive Analysis of Transcriptomic Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma.". Clin Mol Hepatol 31(1):e110-e112, 2024. e-Pub 2024. PMID: 39355874.
22. De B, Dogra P, Zaid M, Elganainy D, Sun K, Amer AM, Wang C, Rooney MK, Chang E, Kang HC, Wang Z, Bhosale P, Odisio BC, Newhook TE, Tzeng CD, Cao HST, Chun YS, Vauthey JN, Lee SS, Kaseb A, Raghav K, Javle M, Minsky BD, Noticewala SS, Holliday EB, Smith GL, Koong AC, Das P, Cristini V, Ludmir EB, Koay EJ. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. medRxiv (Preprint). e-Pub 2024. PMID: 39314943.
23. Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark 41(1):83-91, 2024. e-Pub 2024. PMID: 39269823.
24. Dogra P, Shinglot V, Ruiz-Ramirez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. Mol Cancer 23(1):156, 2024. e-Pub 2024. PMID: 39095771.
25. Yim SY, Lee SH, Baek SW, Sohn B, Jeong YS, Kang SH, Park K, Park H, Lee SS, Kaseb AO, Park YN, Leem SH, Curran MA, Kim JH, Lee JS. Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial. Clin Mol Hepatol 30(4):807-823, 2024. e-Pub 2024. PMID: 39038962.
26. Chamseddine S, LaPelusa M, Carter K, Nguyen V, Mohamed YI, Sakr Y, Rojas-Hernandez CM, Hatia RI, Hassan M, Goss JA, Elsayes KM, Rashid A, Sun R, Tran Cao HS, Amin HM, Kaseb AO. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report. J Gastrointest Oncol 15(3):1324-1330, 2024. e-Pub 2024. PMID: 38989410.
27. Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey JN, Kaseb AO. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist 29(6):e803-e810, 2024. e-Pub 2024. PMID: 38159256.
28. Abdelrahim, M, Esmail, A, Divatia, M, Xu, J, Kodali, S, Victor, DW, Brombosz, EW, Connor, AA, Saharia, A, Elaileh, A, Kaseb, A, Ghobrial, RM. Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma. Journal of Clinical Medicine 13(11), 2024. e-Pub 2024. PMID: 38892779.
29. Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. J Clin Oncol 42(15):1830-1850, 2024. e-Pub 2024. PMID: 38502889.
30. Chang E, Wong FCL, Chasen BA, Erwin WD, Das P, Holliday EB, Koong AC, Ludmir EB, Minsky BD, Noticewala SS, Smith GL, Taniguchi CM, Rodriguez MJ, Beddar S, Martin-Paulpeter RM, Niedzielski JS, Sawakuchi GO, Schueler E, Perles LA, Xiao L, Szklaruk J, Park PC, Dasari AN, Kaseb AO, Kee BK, Lee SS, Overman MJ, Willis JA, Wolff RA, Tzeng CD, Vauthey JN, Koay EJ. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr 8(3), 2024. e-Pub 2024. PMID: 38730548.
31. Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. The Lancet Gastroenterology and Hepatology 9(4):310-322, 2024. e-Pub 2024. PMID: 38364832.
32. Dogra P, Shinglot V, Ruiz-Ramirez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. medRxiv, 2024. e-Pub 2024. PMID: 38559070.
33. Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietharn B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ, Pinter M. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma. JHEP Reports 6(2):100982, 2024. e-Pub 2024. PMID: 38274490.
34. Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs 42(1):127-135, 2024. e-Pub 2024. PMID: 38270822.
35. Dayyani, F, Baretti, M, Lee, SS, He, AR, Kim, RD, Lin, BS, Enzler, T, Al Hallak, MN, Ulahannan, SV, Davis, SL, Burgoyne, AM, Tweardy, D, Harding, JJ, Kaseb, A, De Achaval, S, Alibhai, I, Kauh, J. A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma. Journal of Clinical Oncology 42(3):TPS577-TPS577, 2024. e-Pub 2024.
36. Emiloju, OE, Yin, J, Koubek, E, Reid, JM, Borad, MJ, Lou, Y, Seetharam, M, Edelman, MJ, Jiang, Y, Kaseb, A, Posey, JA, Davis, SL, Gores, GJ, Roberts, LR, Takebe, N, Wahner Hendrickson, AE, Kaufmann, SH, Hubbard, J, Costello, BA. Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort. Journal of Clinical Oncology 42(3):507, 2024. e-Pub 2024.
37. Chan, SL, Kaseb, A, Shi, W, Alexander, L, Meng, X, Park, CH, Ryan, K, Vogel, A. Patient-reported outcomes (PROs) <65 or ‡ 65 years old (yo) from CARES-310 camrelizumab + rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
38. Haro-Silerio, JI, Fox, DA, Bhamidipati, D, Hu, Z, Koay, EJ, Ludmir, EB, Tran Cao, HS, Vauthey, JN, Newhook, TE, Tzeng, CD, Chun, YS, Mahvash, A, Metwalli, ZA, Habibollahi, P, Cox, V, Kang, H, Chatterjee, D, Kaseb, A, Javle, M, Lee, SS. Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). Journal of Clinical Oncology 42(3):458, 2024. e-Pub 2024.
39. Lapelusa, M, Chamseddine, SM, Xiao, L, Hasanov, E, Bhosale, PR, Abugabal, YI, Yavuz, BG, Yadav, SS, Cao, HS, Xu, L, Hu, Z, Lee, SS, Sakamuri, D, Curran, M, Jindal, S, Duda, GD, Sharma, P, Qayyum, A, Kaseb, A. Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
40. Yalcin, S, Lacin, S, Kaseb, A, Peynircioğlu, B, Cantasdemir, M, Çil, BE, Hurmuz, P, Doğrul, AB, Bozkurt, MF, Abali, H, Akhan, O, Şimşek, H, Sahin, B, Aykan, FN, Yücel, İ, Tellioğlu, G, Selçukbiricik, F, Philip, PA. A Post-International Gastrointestinal Cancers’ Conference (IGICC) Position Statements. Journal of Hepatocellular Carcinoma 11:953-974, 2024. e-Pub 2024. PMID: 38832120.
41. Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 11:455-461, 2024. e-Pub 2024. PMID: 38463542.
42. Maen A, Gok Yavuz B, Mohamed YI, Esmail A, Lu J, Mohamed A, Azmi AS, Kaseb M, Kasseb O, Li D, Gocio M, Kocak M, Selim A, Ma Q, Kaseb AO. Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Front Pharmacol 15:1291212, 2024. e-Pub 2024. PMID: 38379905.
43. Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10415):1835-1847, 2023. e-Pub 2023. PMID: 37871608.
44. Joerg V, Scheiner B, D Alessio A, Fulgenzi CAM, Schönlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phen S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ, Schulze K, von Felden J. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy. Hepatology Communications 7(11), 2023. e-Pub 2023. PMID: 37889520.
45. Swords DS, Newhook TE, Tzeng CD, Massarweh NN, Chun YS, Lee S, Kaseb AO, Ghobrial M, Vauthey JN, Tran Cao HS. Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma. Ann Surg Oncol 30(12):7309-7318, 2023. e-Pub 2023. PMID: 37679537.
46. Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A, Group CS. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310). The Lancet 402(10408):1133-1146, 2023. e-Pub 2023. PMID: 37499670.
47. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Guevara EY, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. American Journal of Gastroenterology 118(9):1609-1617, 2023. e-Pub 2023. PMID: 37307533.
48. Lin YM, Fellman BM, Taiji R, Paolucci I, Silva JAM, Koay EJ, Avritscher R, Mahvash A, Holliday EB, Lee SS, Kaseb AO, Das P, Vauthey JN, Odisio BC. Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg 27(9):1867-1875, 2023. e-Pub 2023. PMID: 37268830.
49. Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist 28(8):714-721, 2023. e-Pub 2023. PMID: 36952233.
50. El-Serag HB, Ward JW, Asrani SK, Singal AG, Rich N, Thrift AP, Deshpande S, Turner BJ, Kaseb AO, Harrison AC, Fortune BE, Kanwal F. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol 21(9):2183-2192, 2023. e-Pub 2023. PMID: 37086825.
51. Kothari AN, Massarweh NN, Flitcroft MA, Newhook T, Tzeng CD, Chun YS, Kaseb AO, Vauthey JN, Tran Cao HS. Evaluating the benefit of surgical resection for hepatocellular carcinoma with multifocality or intrahepatic vascular invasion. HPB (Oxford) 25(7):758-765, 2023. e-Pub 2023. PMID: 37085394.
52. Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang JY, Pandit SK, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A 120(19):e2300706120, 2023. e-Pub 2023. PMID: 37126700.
53. Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang J, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. bioRxiv, 2023. e-Pub 2023. PMID: 36945365.
54. Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Mohamed YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma. Liver International 43(3):695-707, 2023. e-Pub 2023. PMID: 36577703.
55. Moawad AW, Morshid A, Khalaf AM, Elmohr MM, Hazle JD, Fuentes D, Badawy M, Kaseb AO, Hassan M, Mahvash A, Szklaruk J, Qayyum A, Abusaif A, Bennett WC, Nolan TS, Camp B, Elsayes KM. Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation. Sci Data 10(1):33, 2023. e-Pub 2023. PMID: 36653372.
56. Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D'Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 15(11):1900-1912, 2023. e-Pub 2023. PMID: 38077640.
57. Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology 101(11):730-737, 2023. e-Pub 2023. PMID: 37467732.
58. Wu YL, van Hyfte G, Ozbek U, Reincke M, Gampa A, Mohamed YI, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, Kudo M, Pinato DJ, Ang C. Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Front Oncol 13:1128569, 2023. e-Pub 2023. PMID: 36865801.
59. Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget 13(1):1314-1321, 2022. e-Pub 2022. PMID: 36473155.
60. Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H. Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nat Commun 13(1):7477, 2022. e-Pub 2022. PMID: 36463294.
61. Muñoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA. Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Scientific reports 12(1):14449, 2022. e-Pub 2022. PMID: 36002545.
62. Lee SH, Yim SY, Jeong YS, Li QX, Kang SH, Sohn BH, Kumar SV, Shin JH, Choi YR, Shim JJ, Kim H, Kim J, Kim S, Guo S, Johnson RL, Kaseb A, Kang KJ, Chun YS, Jang HJ, Lee BG, Woo HG, Ha MJ, Akbani R, Roberts LR, Wheeler DA, Lee JS. Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. Hepatology 76(6):1634-1648, 2022. e-Pub 2022. PMID: 35349735.
63. Mohamed A, Azmi AS, Asa SL, Tirumani SH, Mahipal A, Cjakrabarti S, Bajor D, Selfridge JE, Kaseb AO. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination. Curr Oncol 29(11):9018-9030, 2022. e-Pub 2022. PMID: 36421360.
64. Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312). The lancet oncology 23(8):995-1008, 2022. e-Pub 2022. PMID: 35798016.
65. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 28(8):1599-1611, 2022. e-Pub 2022. PMID: 35739268.
66. Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatology Communications 6(7):1776-1785, 2022. e-Pub 2022. PMID: 35481940.
67. Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 10(6), 2022. e-Pub 2022. PMID: 35710293.
68. Bencheqroun H, Ahmed Y, Kocak M, Villa E, Barrera C, Mohiuddin M, Fortunet R, Iyoha E, Bates D, Okpalor C, Agbosasa O, Mohammed K, Pondell S, Mohamed A, Mohamed YI, Gok Yavuz B, Kaseb MO, Kasseb OO, Gocio MY, Tu PT, Li D, Lu J, Selim A, Ma Q, Kaseb AO. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2. Pathogens 11(5), 2022. e-Pub 2022. PMID: 35631072.
69. Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey JN, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel) 14(8), 2022. e-Pub 2022. PMID: 35454808.
70. Abdelsalam ME, Figueira TMA, Ensor J, Tam AL, Avritscher R, Kaseb A, Gupta S. The Impact of the Use of C-Arm Cone-Beam CT During Chemoemboliza-tion for Hepatocellular Carcinoma. Current Medical Imaging 18(4):372-380, 2022. e-Pub 2022. PMID: 34420509.
71. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76(4):862-873, 2022. e-Pub 2022. PMID: 34902530.
72. McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, Hobeika MJ, Lunsford KE, Victor DW, Shetty A, McFadden RS, Abdelrahim M, Kaseb A, Divatia M, Yu N, Nolte Fong J, Moore LW, Nguyen DT, Graviss EA, Gaber AO, Vauthey JN, Ghobrial RM. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. American Journal of Transplantation 22(3):823-832, 2022. e-Pub 2022. PMID: 34856069.
73. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
74. Lithy RM, Elbaz T, H Abdelmaksoud A, M Nabil M, Rashed N, Omran D, Kaseb AO, O Abdelaziz A, I Shousha H. Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals. Eur J Gastroenterol Hepatol 34(2):227-234, 2022. e-Pub 2022. PMID: 33208688.
75. Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang Y, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJ. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 14(1), 2022. e-Pub 2022. PMID: 35008350.
76. Awiwi MO, Elsayes KM, Mohamed YI, Altameemi L, Gjoni M, Irshad OM, Sayed Ahmed A, Kaseb AO, Salem U. The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. J Hepatocell Carcinoma 9:913-927, 2022. e-Pub 2022. PMID: 36065424.
77. Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma 9:823-837, 2022. e-Pub 2022. PMID: 35996397.
78. Wang Z, Kaseb AO, Amin HM, Hassan MM, Wang W, Morris JS. Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer. J Am Stat Assoc 117(538):533-546, 2022. e-Pub 2022. PMID: 36090952.
79. Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 9:1065-1079, 2022. e-Pub 2022. PMID: 36254201.
80. Kaseb AO, Haque A, Vishwamitra D, Hassan MM, Xiao L, George B, Sahu V, Mohamed YI, Carmagnani Pestana R, Lombardo JL, Avritscher R, Yao JC, Wolff RA, Rashid A, Morris JS, Amin HM. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol 12:986305, 2022. e-Pub 2022. PMID: 36276070.
81. Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World journal of gastroenterology 27(47):8166-8181, 2021. e-Pub 2021. PMID: 35068861.
82. Zheng J, Daniel CR, Hatia RI, Stuff J, Abdelhakeem AA, Rashid A, Chun YS, Jalal PK, Kaseb AO, Li D, Hassan MM. Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A USA-Based Study. Hepatology 74(6):3161-3173, 2021. e-Pub 2021. PMID: 34233041.
83. Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellini A, Pinato DJ. Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. Liver Cancer 10(6):583-592, 2021. e-Pub 2021. PMID: 34950181.
84. Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer 157:140-152, 2021. e-Pub 2021. PMID: 34508996.
85. Moussa I, Day RS, Li R, Kaseb A, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer medicine 10(20):7308-7319, 2021. e-Pub 2021. PMID: 34535983.
86. Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 9(9), 2021. e-Pub 2021. PMID: 34518290.
87. Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-In Pilot Randomized Clinical Trial. Journal of pain and symptom management 62(2):223-232.e1, 2021. e-Pub 2021. PMID: 33388382.
88. Galle, PR, Finn, RS, Qin, SK, Ikeda, M, Zhu, AX, Kim, TY, Kudo, M, Breder, V, Merle, P, Kaseb, A, Li, D, Mulla, S, Verret, W, Xu, DZ, Hernandez, S, Ding, B, Liu, J, Huang, C, Lim, HY, Cheng, AL, Ducreux, M. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150). The lancet oncology 22(7):991-1001, 2021. e-Pub 2021. PMID: 34051880.
89. Moussa I, Day RS, Li R, Du XL, Kaseb AO, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients 13(6), 2021. e-Pub 2021. PMID: 34208122.
90. Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology 73(6):2278-2292, 2021. e-Pub 2021. PMID: 32931023.
91. Yao, S, Janku, F, Subbiah, V, Stewart, J, Patel, SP, Kaseb, A, Westin, SN, Naing, A, Tsimberidou, AM, Hong, DS, Piha-Paul, SA, Shi, N, Johnston, A, Bomalaski, J, Fu, S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. British journal of cancer 124(9):1533-1539, 2021. e-Pub 2021. PMID: 33674736.
92. Pfister, D, Núñez, NG, Pinyol, R, Govaere, O, Pinter, M, Szydlowska, M, Gupta, R, Qiu, M, Deczkowska, A, Weiner, A, Müller, F, Sinha, A, Friebel, E, Engleitner, T, Lenggenhager, D, Moncsek, A, Heide, D, Stirm, K, Kosla, J, Kotsiliti, E, Leone, V, Dudek, M, Yousuf, S, Inverso, D, Singh, I, Teijeiro, A, Castet, F, Montironi, C, Haber, PK, Tiniakos, D, Bedossa, P, Cockell, SJ, Younes, R, Vacca, M, Marra, F, Schattenberg, JM, Allison, M, Bugianesi, E, Ratziu, V, Pressiani, T, D’Alessio, A, Personeni, N, Rimassa, L, Daly, AK, Scheiner, B, Pomej, K, Kirstein, MM, Vogel, A, Peck-Radosavljevic, M, Hucke, F, Finkelmeier, F, Waidmann, O, Trojan, J, Schulze, K, Wege, H, Koch, S, Weinmann, A, Bueter, M, Rössler, F, Siebenhüner, A, De Dosso, S, Mallm, JP, Umansky, V, Jugold, M, Luedde, T, Schietinger, A, Schirmacher, P, Emu, B, Augustin, HG, Billeter, AT, Müller-Stich, BP, Kikuchi, H, Duda, DG, Kütting, F, Waldschmidt, D, Ebert, MP, Rahbari, NN, Mei, HE, Schulz, AR, Ringelhan, M, Malek, NP, Spahn, S, Bitzer, M, Ruiz de Galarreta, M, Lujambio, A, Dufour, JF, Marron, TU, Kaseb, A, Kudo, M, Huang, YH, Djouder, N, Wolter, K, Zender, L, Marche, PN, Decaens, T, Pinato, DJ, Rad, R, Mertens, JC, Weber, A, Unger, K, Meissner, F, Roth, S, Jilkova, ZM, Claassen, M, Anstee, QM, Amit, I, Knolle, PA, Becher, B, Llovet, JM, Heikenwalder, M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592(7854):450-456, 2021. e-Pub 2021. PMID: 33762733.
93. Mohamed YI, Lee S, Xiao L, Hassan MM, Qayyum A, Hiatia R, Pestana RC, Haque A, George B, Rashid A, Duda DG, Elghazaly H, Wolff RA, Morris JS, Yao J, Amin HM, Kaseb AO. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget 12(8):756-766, 2021. e-Pub 2021. PMID: 33889299.
94. Qayyum A, Bhosale P, Aslam R, Avritscher R, Ma J, Pagel MD, Sun J, Mohamed Y, Rashid A, Beretta L, Kaseb AO. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY) 46(3):1008-1015, 2021. e-Pub 2021. PMID: 32974761.
95. Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Miller E, Sturgis EM, Foreman JT, Angelidakis G, Ahmed S, Ferrajoli A, Samaniego F, Hawk ET, Hwang JP. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Supportive Care in Cancer 29(1):97-105, 2021. e-Pub 2021. PMID: 32314052.
96. Chang KY, Chiang NJ, Wu SY, Yen CJ, Chen SH, Yeh YM, Li CF, Feng X, Wu K, Johnston A, Bomalaski JS, Wu BW, Gao J, Subudhi SK, Kaseb AO, Blando JM, Yadav SS, Szlosarek PW, Chen LT. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology 10(1):1943253, 2021. e-Pub 2021. PMID: 34290906.
97. Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1129-1145, 2021. e-Pub 2021. PMID: 34527608.
98. Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol 38(36):4317-4345, 2020. e-Pub 2020. PMID: 33197225.
99. Muñoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Avritscher R, Bouchard R, Kaseb A, Schachtschneider KM, Rao A, Sheth RA. Molecularly targeted photothermal ablation improves tumor specificity and immune modulation in a rat model of hepatocellular carcinoma. Commun Biol 3(1):783, 2020. e-Pub 2020. PMID: 33335270.
100. Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33028690.
101. Thomas MA, Mahvash A, Abdelsalam M, Kaseb AO, Kappadath SC. Planning dosimetry for (90) Y radioembolization with glass microspheres: Evaluating the fidelity of (99m) Tc-MAA and partition model predictions. Med Phys 47(10):5333-5342, 2020. e-Pub 2020. PMID: 32790882.
102. Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol 12(9):628-640, 2020. e-Pub 2020. PMID: 33033569.
103. Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, Lu Q, Gao H, Jiang H, Wang H, Yuan D, Ma H, Wang H, Li Z, Zhai B. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clin Cancer Res 26(15):3979-3989, 2020. e-Pub 2020. PMID: 32371538.
104. Angelidakis G, Krishnan S, Cabrera NL, Jiang Y, Pushparaji B, Kaseb A, Torres HA. Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients With Hepatocellular Carcinoma. Hepatology 72(2):775-777, 2020. e-Pub 2020. PMID: 31944343.
105. Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 32868393.
106. Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32664319.
107. Gjyshi O, Boyce-Fappiano D, Pezzi TA, Ludmir EB, Xiao L, Kaseb A, Amini B, Yeboa DN, Bishop AJ, Li J, Rhines LD, Tatsui CE, Briere TM, Ghia AJ. Spine stereotactic radiosurgery for metastases from hepatobiliary malignancies: patient selection using PRISM scoring. J Neurooncol 148(2):327-334, 2020. e-Pub 2020. PMID: 32358642.
108. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382(20):1894-1905, 2020. e-Pub 2020. PMID: 32402160.
109. Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol 16(15):975-989, 2020. e-Pub 2020. PMID: 32352320.
110. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res 26(8):1924-1931, 2020. e-Pub 2020. PMID: 31852833.
111. Okuno M, Newhook TE, Joechle K, Kawaguchi Y, De Bellis M, Tzeng CD, Chun YS, Aloia TA, Shindoh J, Kaseb AO, Vauthey JN. Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma?. HPB (Oxford) 22(4):545-552, 2020. e-Pub 2020. PMID: 31533893.
112. Avritscher R, Jo N, Polak U, Cortes AC, Nishiofuku H, Odisio BC, Takaki H, Tam AL, Melancon MP, Yevich S, Qayyum A, Kaseb A, Kichikawa K, Gupta S, Goldberg SN, Chang SH. Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 43(2):311-321, 2020. e-Pub 2020. PMID: 31591689.
113. Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology 98(12):836-846, 2020. e-Pub 2020. PMID: 33027788.
114. Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 7:117-131, 2020. e-Pub 2020. PMID: 32984089.
115. Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma 7:143-153, 2020. e-Pub 2020. PMID: 32984091.
116. Khalaf AM, Fuentes D, Morshid A, Kaseb AO, Hassan M, Hazle JD, Elsayes KM. Hepatocellular carcinoma response to transcatheter arterial chemoembolisation using automatically generated pre-therapeutic tumour volumes by a random forest-based segmentation protocol. Clin Radiol 74(12):974.e13-974.e20, 2019. e-Pub 2019. PMID: 31521326.
117. Qayyum A, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, Sun J, Pestana RC, Avritscher R, Hassan MM, Amin H, Rashid A, Wistuba II, Ehman RL, Ma J, Kaseb AO. Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. J Immunother Cancer 7(1):329, 2019. e-Pub 2019. PMID: 31779702.
118. Kaseb AO, Sanchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res 25(20):6107-6118, 2019. e-Pub 2019. PMID: 31363003.
119. Morshid A, Elsayes KM, Khalaf AM, Elmohr MM, Yu J, Kaseb AO, Hassan M, Mahvash A, Wang Z, Hazle JD, Fuentes D. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell 1(5), 2019. e-Pub 2019. PMID: 31858078.
120. Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res 7(9):1390-1395, 2019. e-Pub 2019. PMID: 31289040.
121. George B, George SK, Shi W, Haque A, Shi P, Eskandari G, Axelson M, Larsson O, Kaseb AO, Amin HM. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma. J Hematol Oncol 12(1):80, 2019. e-Pub 2019. PMID: 31340850.
122. Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 129(8):3324-3338, 2019. e-Pub 2019. PMID: 31305264.
123. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 5(6):824-830, 2019. e-Pub 2019. PMID: 30998813.
124. Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM. Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study. J Comput Assist Tomogr. e-Pub 2019. PMID: 31082984.
125. Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM. Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study. J Comput Assist Tomogr 43(3):499-506, 2019. e-Pub 2019. PMID: 31082956.
126. Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol 133:54-61, 2019. e-Pub 2019. PMID: 30935582.
127. Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP. Sofosbuvir-Based Therapy in Hepatitis C Virus-infected Cancer Patients: A Prospective Observational Study. Am J Gastroenterol 114(2):250-257, 2019. e-Pub 2019. PMID: 30410039.
128. Sánchez NS, Kahle MP, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Javle M, Kaseb A, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Mills Shaw KR, Meric-Bernstam F. Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923868.
129. Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget 9(102):37721-37732, 2018. e-Pub 2018. PMID: 30701027.
130. Ganeshan D, Szklaruk J, Kaseb A, Kattan A, Elsayes KM. Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. Abdom Radiol (NY) 43(12):3340-3348, 2018. e-Pub 2018. PMID: 29948061.
131. Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-Shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab T, Shroff RT, Javle M. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol 2:1-12, 2018. e-Pub 2018. PMID: 35135097.
132. Hosry J, Angelidakis G, Kaseb A, Jiang Y, Torres HA. Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study. Clin Infect Dis 67(10):1635-1636, 2018. e-Pub 2018. PMID: 30124786.
133. Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. Int J Radiat Oncol Biol Phys 102(2):451-461, 2018. e-Pub 2018. PMID: 30191875.
134. Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med 7(10):4880-4892, 2018. e-Pub 2018. PMID: 30152073.
135. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 3(5):337-348, 2018. e-Pub 2018. PMID: 29548617.
136. Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, Qayyum A, Kaseb A, Sheth RA. Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma. J Clin Med 7(4), 2018. e-Pub 2018. PMID: 29661994.
137. Odisio BC, Kaseb AO. Anti-angiogenic therapy in the setting of TACE: an elusive synergy?. Lancet Gastroenterol Hepatol 3(1):5-6, 2018. e-Pub 2018. PMID: 28988686.
138. Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA. Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. J Hepatocell Carcinoma 5:81-86, 2018. e-Pub 2018. PMID: 30123783.
139. Kaseb AO. Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma?. Lancet Oncol 18(12):1560-1561, 2017. e-Pub 2017. PMID: 29107680.
140. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
141. Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw 15(9):1111-1120, 2017. e-Pub 2017. PMID: 28874596.
142. Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging 44(6):969-978, 2017. e-Pub 2017. PMID: 27942837.
143. Kutlu OC, Chan JA, Aloia TA, Chun YS, Kaseb AO, Passot G, Yamashita S, Vauthey JN, Conrad C. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. Cancer 123(10):1817-1827, 2017. e-Pub 2017. PMID: 28085184.
144. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology 93(4):233-242, 2017. e-Pub 2017. PMID: 28683459.
145. Economides MP, Mahale P, Kyvernitakis A, Turturro F, Kantarjian H, Naing A, Hosry J, Shigle TL, Kaseb A, Torres HA. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther 44(11-12):1235-1241, 2016. e-Pub 2016. PMID: 27730654.
146. Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget 7(43):69916-69926, 2016. e-Pub 2016. PMID: 27655712.
147. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget 7(41):67521-67531, 2016. e-Pub 2016. PMID: 27589687.
148. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol 65(4):862-4, 2016. e-Pub 2016. PMID: 27255582.
149. Yamashita S, Vauthey JN, Kaseb AO, Aloia TA, Conrad C, Hassan MM, Passot G, Raghav KP, Shama MA, Chun YS. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. J Gastrointest Surg 20(10):1725-31, 2016. e-Pub 2016. PMID: 27456016.
150. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. e-Pub 2016. PMID: 27622582.
151. Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clin Cancer Res 22(5):1256-64, 2016. e-Pub 2016. PMID: 26459179.
152. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 34(3):219-26, 2016. e-Pub 2016. PMID: 26503201.
153. Jauch SF, Morris VK, Jensen CT, Kaseb AO. Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. Pancreatology 16(1):153-6, 2016. e-Pub 2016. PMID: 26456669.
154. Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 3:1-7, 2016. e-Pub 2016. PMID: 27574586.
155. Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther 9:773-80, 2016. e-Pub 2016. PMID: 26929648.
156. Kaseb A, Xiao L, Hassan MM, Abbruzzese JL, Cheung S, Mohamed H, Vierling J, Jalal P, J-S L, Wallace MJ, J-N V, Aloia TA, Curley SA, Rashid A, Morris J. Development and Validation of a modified Child-Turcotte-Pugh score to predict survival in patients with hepatocellular carcinoma. J Clin Oncol. e-Pub 2016.
157. Atta MM, Atta HM, Gad MA, Rashed LA, Said EM, Hassanien Sel-S, Kaseb AO. Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients. J Hepatocell Carcinoma 3:19-24, 2016. e-Pub 2016. PMID: 27574588.
158. Mitchell J, Tinkey PT, Avritscher R, Van Pelt C, Eskandari G, Konnath George S, Xiao L, Cressman E, Morris JS, Rashid A, Kaseb AO, Amin HM, Uthamanthil R. Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology 91(2):90-100, 2016. e-Pub 2016. PMID: 27305144.
159. Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, Kaseb AO, Shi P, Amin HM. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma. Mol Cancer 14(1):324, 2015. e-Pub 2015. PMID: 25777566.
160. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget 6(29):28453-62, 2015. e-Pub 2015. PMID: 26164085.
161. Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget 6(25):21193-207, 2015. e-Pub 2015. PMID: 26098859.
162. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 8:58, 2015. e-Pub 2015. PMID: 26022204.
163. Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. e-Pub 2015. PMID: 25836985.
164. Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, Kaseb AO, Shi P, Amin HM. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma. Mol Cancer 14:53, 2015. e-Pub 2015. PMID: 25884514.
165. Mohamed A, Chenna A, Abdelfatah M, Sanjay J, Mohammad MK, Saber I, Kauh J, Elhammali B, Kaseb A. Microvessel Density Analysis in Patients with Viral Hepatitis-Related Hepatocellular Carcinoma. J Gastrointest Cancer. e-Pub 2015. PMID: 25645584.
166. Torres HA, Mahale P, Blechacz B, Miller E, Kaseb A, Herlong HF, Fowler N, Jiang Y, Raad II, Kontoyiannis DP. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw 13(1):41-50, 2015. e-Pub 2015. PMID: 25583768.
167. Kaseb AO. Welcome to Journal of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2:1-2, 2015. e-Pub 2015. PMID: 27508188.
168. Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol 5(6):408-413, 2014. e-Pub 2014. PMID: 25436118.
169. Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A, Kim BH, Kim WB, Yeon JE, Byun KS, Chu IS, Kim SS, Wang XW, Thorgeirsson SS, Luk JM, Kang KJ, Heo J, Park YN, Lee JS. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med 11(12):e1001770, 2014. e-Pub 2014. PMID: 25536056.
170. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget 5(10):3012-22, 2014. e-Pub 2014. PMID: 24931142.
171. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 106(5), 2014. e-Pub 2014. PMID: 24815863.
172. Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, Shousha HI, Barakat AB, El-Desouky ED, Zayed NA, Ahmed OS, El-Din Youssef AS, Kaseb AO, Abd El-Aziz AO, Bahnassy AA. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev 14(11):6721-6, 2014. e-Pub 2014. PMID: 24377595.
173. Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M, Aloia TA, Curley S, Abbruzzese JL, Hassan MM. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology 86(2):63-71, 2014. e-Pub 2014. PMID: 24401634.
174. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surg Clin North Am 93(6):1423-50, 2013. e-Pub 2013. PMID: 24206860.
175. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol 3(4):344-8, 2013. e-Pub 2013. PMID: 24674408.
176. Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon alpha-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 119(18):3334-42, 2013. e-Pub 2013. PMID: 23821538.
177. Frenette CT, Boktour M, Burroughs SG, Kaseb A, Aloia TA, Galati J, Gaber AO, Monsour H, Ghobrial RM. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int 26(7):734-9, 2013. e-Pub 2013. PMID: 23701126.
178. Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 5(6):332-5, 2013. e-Pub 2013. PMID: 23805358.
179. Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Mol Carcinog. e-Pub 2013. PMID: 23776098.
180. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. Oncotarget 4(1):153-162, 2013. e-Pub 2013. PMID: 23391555.
181. Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 85(4):197-203, 2013. e-Pub 2013. PMID: 24051705.
182. Myers AL, Zhang YP, Kramer MA, Bornmann WG, Kaseb A, Yang P, Tran HT. A Practical Synthesis and X-ray Crystallographic Analysis of Dithymoquinone, a Photodimer of Thymoquinone. Lett Org Chem 9(10):762-766, 2012. e-Pub 2012. PMID: 24883052.
183. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55(5):1443-52, 2012. e-Pub 2012. PMID: 22105560.
184. Mahale P, Kaseb A, Davila M, Torres HA. The Effect of Transcatheter Arterial Chemoembolization on Hepatitis C viremia. Oncologist 17(9):e21-3, 2012. e-Pub 2012. PMID: 23002170.
185. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 82(2):67-74, 2012. e-Pub 2012. PMID: 22327795.
186. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 50(8):1191-8, 2011. e-Pub 2011. PMID: 21793641.
187. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29(29):3892-9, 2011. e-Pub 2011. PMID: 21911725.
188. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 29(4):694-9, 2011. e-Pub 2011. PMID: 20107864.
189. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer 117(11):2478-88, 2011. e-Pub 2011. PMID: 24048796.
190. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology 80(5-6):373-81, 2011. e-Pub 2011. PMID: 21822028.
191. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. e-Pub 2010. PMID: 21157958.
192. Wilson SR, Greig P, Kaseb AO. Pretreatment assessment of hepatocellular cancer: expert consensus conference. HPB (Oxford) 12(5):300-1, 2010. e-Pub 2010. PMID: 20590902.
193. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8):1938-46, 2010. e-Pub 2010. PMID: 20166205.
194. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49(5):1563-70, 2009. e-Pub 2009. PMID: 19399911.
195. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 145(4):399-405, 2009. e-Pub 2009. PMID: 19303988.
196. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27(6):843-50, 2009. e-Pub 2009. PMID: 19139433.
197. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 50(2):334-41, 2009. e-Pub 2009. PMID: 19070394.
198. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer 123(8):1883-91, 2008. e-Pub 2008. PMID: 18688864.
199. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67(16):7782-8, 2007. e-Pub 2007. PMID: 17699783.
200. Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, Pardee AB, Reddy GP. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A 104(7):2343-8, 2007. e-Pub 2007. PMID: 17283334.
201. Yang H, Yang K, Khafagi A, Tang Y, Carey TE, Opipari AW, Lieberman R, Oeth PA, Lancaster W, Klinger HP, Kaseb AO, Metwally A, Khaled H, Kurnit DM. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A 102(21):7683-8, 2005. e-Pub 2005. PMID: 15914551.

Invited Articles

1. Kaseb, A. Hepatitis-induced Hepatocellular Carcinoma. Gastrointestinal Cancer Research.

Review Articles

1. Akula, V, Chen, L, Acikgoz, Y, Klein, K, Yavuz, BG, Cevik, L, Demir, T, Manne, A, Sahin, I, Kaseb, A, Hasanov, E. Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 40050446.
2. Akyildiz, A, Yavuz, BG, Ismayilov, R, Buyukaksoy, M, Sozen, S, Eid, JR, Avritscher, R, Sunyoung, L, Yalcin, S, Kaseb, A. Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer 56(1), 2025. e-Pub 2025. PMID: 41015600.
3. Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Victor D, Kodali S, Cheah YL, Simon CJ, Noureddin M, Connor A, Saharia A, Moore LW, Heyne K, Kaseb AO, Gaber AO, Ghobrial RM. Transplant Oncology: An Emerging Discipline of Cancer Treatment. Cancers (Basel) 15(22), 2023. e-Pub 2023. PMID: 38001597.
4. Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835569.
5. Lee MS, Kaseb AO, Pant S. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers. Clin Cancer Res 29(17):3267-3274, 2023. e-Pub 2023. PMID: 37092904.
6. Chamseddine S, LaPelusa M, Kaseb AO. Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444618.
7. Omar A, Kaseb A, Elbaz T, El-Kassas M, El Fouly A, Hanno AF, El Dorry A, Hosni A, Helmy A, Saad AS, Alolayan A, Eysa BE, Hamada E, Azim H, Khattab H, Elghazaly H, Tawfik H, Ayoub H, Khaled H, Saadeldin I, Waked I, Barakat EMF, El Meteini M, Hamed Shaaban M, EzzElarab M, Fathy M, Shaker M, Sobhi M, Shaker MK, ElGharib M, Abdullah M, Mokhtar M, Elshazli M, Heikal OMK, Hetta O, ElWakil RM, Abdel Wahab S, Eid SS, Rostom Y, Study Group ELCC. Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 10:1547-1571, 2023. e-Pub 2023. PMID: 37744303.
8. Abdelrahim M, Esmail A, Saharia A, Abudayyeh A, Abdel-Wahab N, Diab A, Murakami N, Kaseb AO, Chang JC, Gaber AO, Ghobrial RM. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers (Basel) 14(7), 2022. e-Pub 2022. PMID: 35406533.
9. Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Hepatocellular Carcinoma Immunotherapy. Annu Rev Med 73:267-278, 2022. e-Pub 2022. PMID: 34606324.
10. Abdelrahim M, Esmail A, Al Saadi N, Zsigmond E, Al Najjar E, Bugazia D, Al-Rawi H, Alsaadi A, Kaseb AO. Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge. Front Pharmacol 13:848676, 2022. e-Pub 2022. PMID: 35462919.
11. Kaseb AO, Mohamed YI, Malek AE, Raad II, Altameemi L, Li D, Kaseb OA, Kaseb SA, Selim A, Ma Q. The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. Pathogens 10(3), 2021. e-Pub 2021. PMID: 33809851.
12. Sahin, IH, Khalil, L, Millett, R, Kaseb, A. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma. Chinese clinical oncology 10(1), 2021. e-Pub 2021. PMID: 33440948.
13. Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol 13:17588359211031141, 2021. e-Pub 2021. PMID: 34377156.
14. Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1195-1207, 2021. e-Pub 2021. PMID: 34595140.
15. Demir T, Lee SS, Kaseb AO. Systemic therapy of liver cancer. Adv Cancer Res 149:257-294, 2021. e-Pub 2021. PMID: 33579425.
16. Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget 11(13):1186-1201, 2020. e-Pub 2020. PMID: 32284794.
17. Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma 7:77-89, 2020. e-Pub 2020. PMID: 32426302.
18. El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review. J Adv Res 17:43-48, 2019. e-Pub 2019. PMID: 31193326.
19. El Kassas M, Tawheed A, Eltabbakh M, Kaseb A. Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves. J Hepatocell Carcinoma 6:183-191, 2019. e-Pub 2019. PMID: 31819865.
20. Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends Mol Med 24(4):395-411, 2018. e-Pub 2018. PMID: 29530485.
21. Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM. Role of Wnt/beta-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma 5:61-73, 2018. e-Pub 2018. PMID: 29984212.
22. Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin 67(5):411-431, 2017. e-Pub 2017. PMID: 28683174.
23. Vishwamitra D, George SK, Shi P, Kaseb AO, Amin HM. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget 8(1):1814-1844, 2017. e-Pub 2017. PMID: 27661006.
24. Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, Kaseb AO. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?. Onco Targets Ther 10:1403-1412, 2017. e-Pub 2017. PMID: 28424556.
25. Abdelsalam ME, Murthy R, Avritscher R, Mahvash A, Wallace MJ, Kaseb AO, Odisio BC. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Hepatocell Carcinoma 3:55-61, 2016. e-Pub 2016. PMID: 27785450.
26. Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma 2:131-42, 2015. e-Pub 2015. PMID: 27508202.
27. Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging 39(5):1070-87, 2014. e-Pub 2014. PMID: 24695938.
28. Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther 7:1927-32, 2014. e-Pub 2014. PMID: 25364263.
29. Shindoh J, Kaseb A, Vauthey JN. Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy. Liver Cancer 2(1):47-54, 2013. e-Pub 2013. PMID: 24159596.
30. Kaseb AO, Abaza YM, Roses RE. Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res 190:247-59, 2013. e-Pub 2013. PMID: 22941025.
31. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 115(21):4895-906, 2009. e-Pub 2009. PMID: 19637355.

Other Articles

1. Kaseb, A, Pawlik, TM Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma. The Lancet 406(10515):2035-2038, 2025. PMID: 41125108.
2. Yim, SY, Lee, SH, Baek, SW, Sohn, BH, Jeong, YS, Kang, SH, Park, K, Park, H, Lee, SS, Kaseb, A, Park, YN, Leem, SH, Curran, M, Kim, JH, Lee, JS Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma. Clinical and Molecular Hepatology 31(2):669-670, 2025. PMID: 40012401.
3. Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. PMID: 38381705.
4. Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nat Commun 14(1):7621, 2023. PMID: 37993437.
5. George B, George SK, Shi W, Haque A, Shi P, Eskandari G, Axelson M, Larsson O, Kaseb AO, Amin HM Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma. J Hematol Oncol 16(1):61, 2023. PMID: 37312210.
6. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69(13):5575-83, 2009. PMID: 19549912.

Editorials

1. Kaseb, A. Access to Medical Research is a Basic Human Right. Journal of Hepatocellular Carcinoma 12:649-657, 2025. PMID: 40171232.
2. Kaseb AO. Editorial: charting the future of hepatocellular carcinoma publications. J Hepatocell Carcinoma 5:51-54, 2018. PMID: 29774205.
3. Kaseb AO. Beyond the basics: the differential effects of demographics and hepatitis status on treatment outcome in hepatocellular carcinoma. Oncology 85(1):41-3, 2013. PMID: 23838536.

Abstracts

1. Kudo M, Chen M, H Chow PK, Kaseb AO, Lee HC, Yopp AC, Becker L, Painter SH, Kovic B, Lian Q, Ma N, Wu C, Qin S, Cheng A. Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. Journal of Clinical Oncology 41(16):4002-4002, 2023. e-Pub 2023.
2. Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang JY, Pandit SK, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. PNAS 120(19), 2023. e-Pub 2023.
3. Tam A, Ensor JE, Ninan E, Kaseb A, George M, Ready A, Hamlin A, Gupta S, Wallacde MJ. Quality improvement initiative for patients undergoing transarterial chemoembolization (TACE). The University of Texas at Austin McCombs Health Care System Symposium, 2012. e-Pub 2012.
4. Subbiah IM, Subbiah V, Kasen AO, Janku F, Wheler J, Naing A, Fu S, Phiha-Paul, SA, Hong DS, Falchook GS, Tsimberidou AM, Kurzrock R. Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred toa Phase I clinic. J Clin Oncol 30(4s), 2012. e-Pub 2012.
5. Shah NN, Hassan M, Xiao L, Abbruzzese JL, Morris J, Kaseb AO. Staging of advanced hepatocellular carcinoma patients in the targeted therapy era. J Clin Oncol 30(4s), 2012. e-Pub 2012.
6. Haque W, Das P, Javle M, Kaseb A, Curley SA, Vauthey JN, Abdalla EK, Delclos ME, Krishnan S, Crane CH. Radiation therapy for intrahepatic cholangiocarcinoma. Gastrointest Cancer Res Suppl 1(s34), 2011. e-Pub 2011.
7. Mahvash A, Murthy R, Avritscher R, Madoff D, Kaseb A. Yttrium-90 resin hepatic arterial radioembolotherapy as a therapeutic adjunct to sorafenib for advanced non-transplantable, non-resectable hepatocellular cfancer. Proceedings of Society of Interventional Radiology, 2011. e-Pub 2011.
8. Mahale P, Kased AO, Davila M, Torres HA. The effect of transcatheter arterial chemoembolization on hepatitis c viruskinetics in patients with HCV associated hepatocellular carcinoma. J Clin Oncol 29(4s), 2011. e-Pub 2011.
9. Kaseb AO, Morris J, Hassan M, Lin E, Xiao L, Abdalla EK, Vauthey J, Abbruzzese JL. IV-HCC: Clinical and prognostic implications of plasma IGF-1 and VEGF in patients with hepatocellular carcinoma. J Clin Oncol 29(4s), 2011. e-Pub 2011.
10. Khanijow V, Kaseb AO, Hassan M, Machicao VI, Hassabo HM, Abbruzzese JL. Hepatitis C as a predictor of treatment outcome in patients with hepatocellular carcinoma treated with the retinoid derivative, TAC-101. J Clin Oncol 29(4s), 2011. e-Pub 2011.
11. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Dose-escalated external beam radiotherapy in unresectable hepatocellular carcinoma. J Clin Oncol 29(4s), 2011. e-Pub 2011.
12. Kaseb AO, Siddiqui AM, Hassan MM, Lin E, Xiao L, Abbruzzese JL, Morris J. Use of IV-BCLC, a new molecular staging for hepatocellular carcinoma, for patient stratification. ASCO 28(15s), 2010. e-Pub 2010.
13. Kaseb AO, Hassan M, Lin E, Xiao L, Kumar V, Lazono RD, Rashid A, Abbruzzese JL, Morris. Effect of incorporating plasma VEGF level into a v-CLIP scoring system on streatification of patients with hepatocellular carcinoma. ASCO GI Cancers Symposium, 2010. e-Pub 2010.
14. Tam AL, Ensor J, Ninan EP, Kaseb A, George M, Ready A, Narvaez A, Gupta S, Wallaced MJ. Quality improvement initiative for patients undergoing transarterial chemoembolization (TACE). Radiological Society of North America 96th Scientific Assembly and Annual Meeting, 2010. e-Pub 2010.
15. Varia AK, Guha S, Hassan M, Kaseb AO. A single multidisciplinary center's experience in the management of hepatitis C virus-induced hepatocellular carcinoma in 184 patients. J Clin Oncol 28(15s), 2010. e-Pub 2010.
16. Hassabo HM, Kaseb AO, Shama MA, Vauthey J, Lozano RD, Curley SA, Li D, Hassan M. Association between prior history of cholecystectomy and hepatocellular carcinoma (HCC) development: A case-control study in the United States. J Clin Oncol 28(15s), 2010. e-Pub 2010.
17. Kaseb AO, Morris J, Hassan M, Iwasaki M, Deaton L, Javle MM, Garrett-Mayer E, Onicescu G, Abbruzzese JL, Thomas MB. Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study. J Clin Oncol 28(15s):312S, 2010. e-Pub 2010.
18. Shama MA, Kaseb AO, Vauthey J, Hassan M, Phan AT, Siddiqui AM, Nooka AK, Abbruzzese JL. Retrospective analyses of 52 patients with fibrolamellar hepatocellular carcinoma. ASCO GI Cancers Symposium, 2010. e-Pub 2010.
19. Masood A, Siddiqui AM, Hassan M, Shama MA, Andejani A, Rashid A, Lozano RD, Abbruzzese JL, Kaseb AO. Prognostic effect of insulin growth factor-1 in hepatocellular carcinoma. ASCO GI Cancers Symposium, 2010. e-Pub 2010.
20. Hassan MM, Kaseb A, Li D, Moghazy D, Vauthey JN, Curley S, Abdalla EK, Abbruzzese JL. The association between diabetes mellitus and hepatocellular carcinoma. AACR, 2009. e-Pub 2009.
21. Kaseb A, Iwasaki I, Javle M, Onicescu G, Garrett-Mayer E, Abbruzzese JL, Thomas MB. Biological Activity of Bevacizumab and Erlotinib in Patients with Advanced Hepatocellular Carcinoma (HCC). J Clin Oncol 27(15s):suppl, 2009. e-Pub 2009.
22. Hassan MM, Thomas M, El-Deeb A, Spitz M, Nguyen N, Chan W, Glover K, Kaseb A, Brown T, Curley S, Vauthey JN, Abdalla E, Lozano R, Ellis L, Patt Y, Abbruzzese JL, Hassan D, Li D. Passive smoking and use of non-cigarette tobacco products in association with risk of hepatocellular carcinoma: A case-control study. AACR, 2008. e-Pub 2008.
23. Hammand N, Philip PA, Shields AF, Sarkar FH, Abbruzzese JL, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, El-Rayes BF. A Phase II Study of Isoflavone, Gemacitabine, and Erlotinib in Locally Advanced (LA) or Metastatic Pancreatic Cancer. J Clin Oncol 26(May 20 suppl; abstr 15540), 2008. e-Pub 2008.
24. Kaseb AO, Banerjee S, Wang Z, Sarkar FH, Ramzi M. Enhanced chemosensitivity to gemcitabine and oxaliplatin by thymoquinone in pancreatic cancer. J Clin Oncol 26(May 20 suppl; abstr 15565), 2008. e-Pub 2008.
25. Kaseb AO, Bansal M, Wollner I, Shah V, Moonka D, Divine G, Abouljoud M. A 10-year retrospective analysis of risk factors, patterns of cancer recurrence, and survival after liver transplant for cirrhosis and hepatocellular carcinoma. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I Vol 25(No. 18S(June 20 suppl)), 2007. e-Pub 2007.
26. Mohemad H, Iwasaki M, Soliman MK, Kaseb A, Torres HA, Li D, Xiao L, Abaza Y, Morris J, Hassan M. Impact of metformin on HCC prognosis in presence and absence of HCV infection. The Liver Meeting, 63rd AASLD Annual Meeting 2012.
27. Torres HA, Kaseb A, Mahale P, Miller E, Frenette C. Telaprevir containing regimen against hepatitis c virus infection in patients with hepatocellular carcinoma awaiting liver transplantation-a case series. The Liver Meeting, 63rd AASLD Annual Meeting 2012.
28. Abdelsalam ME, Ensor J, Kaseb A, Tam AL, Avritscher R, Gupta S. Survival impact of C-arm Cone Beam CT imaging on chemoembolization in patients with hepatocellular carcinoma. The Liver Meeting, 63rd AASLD Annual Meeting 2012.
29. Kaseb AO, Xiao L, Hassan M, Vierling J, Jalal P, Goss J, Abbruzzese JL, Morris J. Development and validation of an Igf-1-modified child-Pugh score to risk stratify hepatocellular carcinoma patients. ILCA 2012 International Meeting.
30. Sahin IH, Morris JS, Xiao L, Hassan M, Abbruzzese JL, Kaseb AO. A modified plasma IGF-MELD score to predict survival in hepatyocellular carcinoma. The Liver Meeting, 63rd AASLD Annual Meeting 2012.

Book Chapters

1. Adams, AM, Kaseb, A, Tran Cao, HS. Hepatocellular carcinoma, 27-39, 2024.
2. Sperandio, RC, Pestana, RC, Kaseb, A. Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma, 177-184, 2022.
3. Demir, T, Lee, SS, Kaseb, A. Systemic therapy of liver cancer, 257-294, 2021.
4. Szklaruk J, Abdalla EK, Kaseb A, Krishnan S. Liver Cancer: Hepatocellular and fibrolamellar hepatocellular carcinoma. In: Oncologic Imaging: A Multiplisciplinary Approach. Elsevier, 95-120, 2012.
5. Bhadkamkar N, Javle M, Arvitscher R, Krishnan S, Kaseb AO. Hepatobiliary Malignancies. In: M.D. Anderson Cancer Center's Manual of Medical Oncology. 2nd. McGraw-Hill, 505-528, 2012.
6. Hongchi J, Linford JW, Kaseb AO. Personalized medicine and targeted therapy of hepatocellular carcinoma. In: Principles of Molecular Diagnostics and Personalized Cancer Therapy. Lippincott Williams & Wilkins, 1-15, 2012.
7. Hassan M, Kaseb A. Epidemiology and Pathogenesis of Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Springer, 1-19, 2010.
8. Kaseb A, Abdel-Hafez S. Kalonji (Thymoquinone). In: Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine. World Scientific Publishing Co., Inc, 257-280, 2009.
9. Kaseb A, Thomas M, Curley S. Gall Bladder and Bile Duct Cancer. In: Holland-Frei Cancer Medicine. 8. People's Medical Publishing House-USA, Part Five, Section 27; 87, 2009.
10. Kaseb A, Thomas M. Chemotherapy and Novel Therapies. In: Hepatocellular Carcinoma: A Practical Approach. Informa Health Care Publishing Co., Inc, 2008.
11. Azmi AS, Mohammad M, Kaseb A, Sarkar F, Mohammad RM. Utility of Animal Models in Pancreatic Cancer Research. In: Pancreatic Cancer. Springer, 577-599, 2008.
12. Kaseb A, Tejwani S. Vaccines in Medical Oncology. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier Publishing Co., Inc, 2006.
13. Kaseb A, Tejwani S. Biological Response Modifiers in Cancer Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier, 2006.
14. Kaseb A, Tejwani S. Cancer Gene Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier, 2006.
15. Kaseb A, Thomas M. The Future: Combination Systemic Therapy for Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Humana Press.

Books (edited and written)

1. Kaseb. Hepatocelluar Carcinoma - Future Outlook. InTech Open Access Publisher, 2012.

Letters to the Editor

1. Sherry, AD, Kaseb, A, Ludmir, EB. Local Control and Extended Survival in Locally Advanced Hepatocellular Carcinoma. JAMA Oncology 11: 670-671, 2025.
2. Lee SH, Jeong YS, Lee S, Sohn BH, Hwang HK, Choi GH, Kang CM, Choi JS, Lee WJ, Cheong JH, Jang HJ, Kaseb A, Roberts L, Yim SY, Chun YS, Lee JS. Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Communications 42: 179-183, 2022.
3. Morris JS, Hassan M, Amin H, Kaseb A. Rejoinder to Sun et al. letter. Hepatology 73: 2614, 2021.
4. Morris JS, Hassan M, Amin H, Kaseb A. Rejoinder to Hou, Liu and Hsu. Hepatology 73: 2612, 2021.
5. Hassan MM, Abdel-Wahab R, Li D, Kaseb AO. Reply: To PMID 25836985. Gastroenterology 149: 1643-4, 2015.
6. Mahale P, Kaseb AO, Hassan MM, Torres HA. Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. Dig Liver Dis 47: 348-9, 2015.
7. Sahin HI, Kaseb A. A comment on 'A morpho-molecular prognostic model for hepatocellular carcinoma'. Br J Cancer 108: 740, 2013.
8. Kaseb AO, Morris JS, Hassan MM, Abbruzzese JL. Reply to A. Goyal et al. J Clin Oncol 30: 1019-1020, 2012.